The 18 references in paper A. Gianoukakis G., C. Dutcus E., N. Batty, M. Guo, M. Baig, A. Gianoukakis G., C. Dutcus E., N. Batty, M. Guo, M. Baig (2018) “Увеличенная длительность ответа на терапию ленватинибом у пациентов с раком щитовидной железы // Prolonged duration of response in lenvatinib responders with thyroid cancer (Russian translation)” / spz:neicon:ogsh:y:2018:i:3:p:53-60

1
Brose M. S., Nutting C. M., Jarzab B. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet
(check this in PDF content)
2
14;384(9940):319–28. DOI: 10.1016/S0140-6736(14)60421-9. PMID: 24768112. 2. Busaidy N. L., Cabanillas M. E. Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. J Thyroid Res 2012;2012:618985.DOI: 10.1155/ 2012/618985. PMID: 22530159.
(check this in PDF content)
3
Cooper D. S., Doherty G. M., Haugen B. R. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19(11):1167–214. DOI: 10.1089/thy.2009.0110. PMID: 19860577.
(check this in PDF content)
4
Dieci M. V., Arnedos M., Andre F., Soria J. C. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov 2013;3(3):264–79. DOI: 10.1158/21598290.CD-12-0362. PMID: 23418312.
(check this in PDF content)
5
Durante C., Haddy N., Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91(8):2892–9. DOI: 10.1210/jc.2005-2838. PMID: 16684830.
(check this in PDF content)
6
Haddad R. I., Schlumberger M., Wirth L. J. et al. Incidence and timing of common adverse events in Lenvatinib treated patients from the SELECT trial and their association with survival outcomes. Endocrine 2017;56(1):121–8. DOI: 10.1007/s12020-017-1233-5. PMID: 28155175.
(check this in PDF content)
7
Laursen R., Wehland M., Kopp S. et al. Effects and role of multikinase inhibitors in thyroid cancer. Curr Pharm Des 2016;22(39):5915–26. DOI: 10.2174/ 1381612822666160614084943. PMID: 27306093.
(check this in PDF content)
8
Matsui J., Funahashi Y., Uenaka T. et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008;14(17):5459–65. DOI: 10.1158/1078- 0432.CCR-07-5270. PMID: 18765537.
(check this in PDF content)
9
Matsui J., Yamamoto Y., Funahashi Y. et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 2008;122(3):664–71. DOI: 10.1002/ijc.23131. PMID: 17943726.
(check this in PDF content)
10
Okamoto K., Kodama K., Takase K. et al. Antitumor activities of the targeted multityrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett 2013;340(1):97–103. DOI: 10.1016/j. canlet. 2013.07.007. PMID: 23856031.
(check this in PDF content)
11
Pacini F., Ito Y., Luster M. et al. Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions. Exp Rev Endocrinol Metab 2012;7:541–54. DOI: 10.1586/eem.12.36.
(check this in PDF content)
12
Pitoia F., Jerkovich F. Selective use of sorafenib in the treatment of thyroid cancer. Drug Des Devel Ther 2016;10: 1119–31. DOI: 10.2147/DDDT.S82972. PMID: 27042004.
(check this in PDF content)
13
Schlumberger M., Tahara M., Wirth L. J. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372(7):621–30. DOI: 10.1056/NEJMoa1406470. PMID: 25671254.
(check this in PDF content)
14
St Bernard R., Zheng L., Liu W. et al. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 2005;146(3):1145–53. DOI: 10.1210/en.2004-1134. PMID: 15564323.
(check this in PDF content)
15
Tohyama O., Matsui J., Kodama K. et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014;2014:638747. DOI: 10.1155/2014/638747. PMID: 25295214.
(check this in PDF content)
16
Worden F. Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer. Ther Adv Med Oncol 2014;6(6):267–79. DOI: 10.1177/1758834014548188. PMID: 25364392.
(check this in PDF content)
17
Xing M., Haugen B. R., Schlumberger M. Progress in molecularbased management of differentiated thyroid cancer. Lancet 2013;381(9871):1058–69. DOI: 10.1016/S0140-6736(13)60109-9. PMID: 23668556.
(check this in PDF content)
18
Yamamoto Y., Matsui J., Matsushima T. et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with
(check this in PDF content)